Fig. 3

Examination of the pathological alterations of MCU in clinical breast cancer. A Immunohistochemical assessment of MCU protein expression levels in BRCA tissue samples from diverse patients based on the Human Protein Atlas. B Depicts representative images of MCU expression in breast cancer tissues at distinct staining stages. C MCU expression levels in breast cancer were evaluated in tumor and non-tumor tissues using data from the Human Protein Atlas. C MCU expression levels in breast cancer were depicted in benign and malignant violin plots. E Comparative analysis of MCU expression in BRCA, with box plots illustrating expression levels across different stages of the disease. F qPCR analysis of MCU in 21 paired BRCA and non-tumor tissues, denoted as N and T for non-tumor and tumor tissues, respectively. G Quantitative PCR demonstrates a significant decrease in MCU expression in breast cancer cells transfected with siMCU. H Assessment of wound healing in the MDA-MB-231 cell line through a wound healing assay. I Evaluation of breast cancer cell invasion using the MDA-MB-231 cell line in a Transwell assay. (J) MCU expression levels in different cancer types, with comparisons between tumor and normal tissues, highlighting statistical significance using asterisks. *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar = 500 µm